Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q2 2023 · 10-Q
Revenue—
Net Income-$47.46M-$47.46MN/M vs Q2 2022 EPS Diluted-$0.72-$0.72N/M vs Q2 2022 Operating Income-$55,624,000N/M Operating Cash Flowderived-$33,221,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$35,354,000N/M ended Jun 30, 2023 · filed Aug 9, 2023 · 40 d after period end